Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma

Br J Haematol. 2016 Aug;174(4):536-40. doi: 10.1111/bjh.14081. Epub 2016 May 12.

Abstract

Response to treatment in patients with a plasma cell disorder is typically measured by evaluating the bone marrow and myeloma markers, including monoclonal protein spike and immunofixation (IFE) in blood and urine, and serum free light chains (sFLCs). Stringent complete response criteria for Multiple Myeloma (MM) patients require a normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. We performed a retrospective chart review to further evaluate these criteria. A total of 142 patient charts were analysed. Of these, 17 patients were found to have an abnormal sFLC ratio, but no other evidence of disease, including normal flow cytometry and normal fluorescence in situ hybridization (FISH) analysis on highly selected plasma cells. In all patients, the abnormal sFLC ratio was caused by abnormalities in the serum kappa light chains. These results suggest that current definitions may need to be revised to take aberrancies related to abnormal immune recovery into account.

Keywords: multiple myeloma; response criteria; serum free light chains.

MeSH terms

  • Adult
  • Aged
  • Female
  • Flow Cytometry
  • Humans
  • Immunoglobulin Light Chains / analysis*
  • Immunoglobulin kappa-Chains / blood
  • Immunoglobulin lambda-Chains / blood
  • In Situ Hybridization, Fluorescence
  • Male
  • Middle Aged
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / immunology
  • Plasma Cells / pathology
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Immunoglobulin Light Chains
  • Immunoglobulin kappa-Chains
  • Immunoglobulin lambda-Chains